◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksJNJ › Revenue

Johnson & Johnson (JNJ) Revenue 2006–TTM

DATA UPDATED 2026-07-11

Johnson & Johnson annual revenue for fiscal TTM was $96.4 billion, an increase of 2.3% from $94.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

JNJ Annual Revenue

Revenue (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$96.4B$94.2B$88.8B$85.2B$80.0B$78.7B$82.6B$82.1B$81.6B$76.5B$71.9B$70.1B$74.3B$71.3B$67.2B$65.0B$61.6B$61.9B$63.7B$61.1B$53.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Quarterly Revenue

Revenue (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$24.1B$24.6B$24.0B$23.7B$21.9B$22.5B$22.5B$22.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More JNJ metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All JNJ financial statements → Interactive JNJ charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.